Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOMPENSE: sotatercept effects on right ventricular compensation in pulmonary arterial hypertension
NL-OMON59054Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in power per beat and Change in right ventricular-pulmonary artery coupling index. Planned start May 2025; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON59054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59054.